Growth Metrics

Bio-Techne (TECH) EBT Margin (2009 - 2026)

Bio-Techne's quarterly EBT Margin came in at 22.87% in Q1 2026, up 1077.0% year-on-year from 1.94% in Q1 2025, and up 33.25% quarter-over-quarter from 17.16% in Q4 2025.

Bio-Techne has reported EBT Margin for 18 years, with the latest figure at 22.87% in Q1 2026.

  • For the quarter ending Q1 2026, EBT Margin rose 1077.0% year-over-year to 22.87%; the trailing twelve-month figure through Mar 2026 stood at 4.98% (down 760.0% YoY), and the FY2025 full-year result was 0.96%, down 1413.0% from the prior year.
  • EBT Margin for Q1 2026 stood at 22.87%, up from 17.16% in the prior quarter.
  • The five-year high for EBT Margin was 5185.8% in Q3 2022, with the low at 34.6% in Q2 2025.
  • Average EBT Margin over 5 years is 320.05%, with a median of 17.9% recorded in 2023.
  • Year-over-year, EBT Margin surged 515965 bps in 2022 and sank 516790 bps in 2023.
  • Tracing TECH's EBT Margin over 5 years: stood at 24.46% in 2022, then plunged by 50 bps to 12.25% in 2023, then increased by 18 bps to 14.43% in 2024, then climbed by 19 bps to 17.16% in 2025, then surged by 33 bps to 22.87% in 2026.
  • The last three EBT Margin figures came in at 22.87% (Q1 2026), 17.16% (Q4 2025), and 16.75% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 Bio-Techne 7.92 Bn 7.71 Bn 208.29 Mn 22.87%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 22.87%
Dec 31, 2025 17.16%
Sep 30, 2025 16.75%
Jun 30, 2025 -34.60%
Mar 31, 2025 12.11%
Dec 31, 2024 14.43%
Sep 30, 2024 13.88%
Jun 30, 2024 10.05%
Mar 31, 2024 20.13%
Dec 31, 2023 12.25%
Sep 30, 2023 17.90%
Jun 30, 2023 29.31%
Mar 31, 2023 27.26%
Dec 31, 2022 24.46%
Sep 30, 2022 5,185.80%
Jun 30, 2022 27.43%
Mar 31, 2022 23.68%
Dec 31, 2021 32.00%
Sep 30, 2021 26.15%
Jun 30, 2021 -17.53%
Mar 31, 2021 18.62%
Dec 31, 2020 25.14%
Sep 30, 2020 19.27%
Jun 30, 2020 34.99%
Mar 31, 2020 24.05%
Dec 31, 2019 81.29%
Sep 30, 2019 9.72%
Jun 30, 2019 11.89%
Mar 31, 2019 26.98%
Dec 31, 2018 12.47%
Sep 30, 2018 10.79%
Jun 30, 2018 -14.03%
Mar 31, 2018 15.24%
Dec 31, 2017 14.10%
Sep 30, 2017 15.88%
Jun 30, 2017 24.17%
Mar 31, 2017 21.62%
Dec 31, 2016 11.52%
Sep 30, 2016 21.28%
Jun 30, 2016 7.75%
Mar 31, 2016 32.44%
Dec 31, 2015 29.26%
Sep 30, 2015 28.34%
Jun 30, 2015 4.97%
Mar 31, 2015 33.95%
Dec 31, 2014 38.02%
Sep 30, 2014 31.89%
Jun 30, 2014 -95.36%
Mar 31, 2014 48.21%
Dec 31, 2013 43.11%
Sep 30, 2013 46.29%
Jun 30, 2013 51.29%
Mar 31, 2013 54.90%
Dec 31, 2012 49.87%
Sep 30, 2012 50.63%
Jun 30, 2012 51.62%
Mar 31, 2012 51.67%
Dec 31, 2011 50.73%
Sep 30, 2011 52.19%
Jun 30, 2011 -112.91%
Mar 31, 2011 59.50%
Dec 31, 2010 55.64%
Sep 30, 2010 57.33%
Jun 30, 2010 -129.30%
Mar 31, 2010 58.96%
Dec 31, 2009 56.01%
Sep 30, 2009 59.68%